	US 12,404,342 B2
	Conjugates for targeted cell surface editing
Elliot C. Woods, Burlingame, CA (US); Han Xiao, East Palo Alto, CA (US); Carolyn R. Bertozzi, Menlo Park, CA (US); and Melissa Gray, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 26, 2022, as Appl. No. 17/822,638.
Application 17/822,638 is a continuation of application No. 16/308,732, granted, now 11,459,398, previously published as PCT/US2017/040411, filed on Jun. 30, 2017.
Claims priority of provisional application 62/357,645, filed on Jul. 1, 2016.
Prior Publication US 2023/0287140 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); A61P 35/00 (2006.01); C07K 19/00 (2006.01); C12N 9/24 (2006.01)

CPC C07K 16/32 (2013.01) [A61P 35/00 (2018.01); C07K 19/00 (2013.01); C12N 9/2402 (2013.01); C12Y 302/01018 (2013.01); C07K 2317/732 (2013.01); C07K 2319/035 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01)]

25 Claims

1. A method of treating cancer in an individual in need thereof, the method comprising administering to the individual a therapeutically effective amount of a conjugate comprising (a) an antibody that binds to a tumor-associated cell surface molecule of a cancer cell and (b) a sialidase conjugated to the antibody, whereupon, after administration to the individual, the sialidase cleaves a sialic acid from the surface of the cancer cell, wherein the sialic acid is a ligand for a sialic acid-binding Ig-like lectin (Siglec) receptor, wherein the sialidase is a prokaryotic sialidase or a eukaryotic sialidase.